SFC news published since 2018. See SFC archived content for earlier news articles.

A new £11 million award from the UK Research Partnership Investment Fund (UKRPIF) will secure a further £23.73 million from industry and charity partners to transform the way medicines are developed in the future.

The award, announced today, will go to CMAC, a world leading centre for medicines research and manufacturing based at the University of Strathclyde. The original concept behind CMAC grew from a collaboration facilitated by the ScotCHEM Research Pool, and its early development was supported by a £700,000 investment from SFC’s SPIRIT fund.

The new investment will be used to establish the CMAC Data Lab, a revolutionary facility designed to create faster, smarter and more efficient ways of developing, manufacturing and regulating medicines.

Helen Cross, Director of Research and Innovation at the Scottish Funding Council, said:

“The success of CMAC stems from a long tradition of world-leading medicines manufacturing research in Scotland and a passion for innovation.

“We are delighted with this announcement and also proud to have played a part in funding CMAC during the early stages of its development.

“I am confident that, through CMAC, UKRPIF funding will unlock further exciting transformations in medicines development, manufacture and supply.”

Scotland’s Minister for Higher Education Graeme Dey said:

“CMAC’s cutting edge research and development of innovative approaches to medicines manufacturing is a prime example of Scottish strengths in life sciences research and innovation.

“Scotland is a world-leader in health research and innovation and this new investment in the Continuous Manufacturing and Crystallisation (CMAC) Data Lab will further strengthen our global reputation.”

Professor Alastair Florence, Director of CMAC and Data Lab lead, said:

“This new £33 million UKRPIF partnership will transform CMAC’s facilities through investment in a suite of innovative technologies that will allow us to address our research goals of human-centric, sustainable and resilient medicines development and manufacture.”

More information on CMAC and today’s funding announcement can be found on the UK Research and Innovation website.

Share: